The most notable strategic choice is prioritising myasthenia gravis (MG) and Sjögren's disease as lead indications while ...

Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, positioning the company for ...

Claritev faces a collapsing moat, heavy debt, and a failed turnaround amid the No Surprises Act and UNH integration. Click to ...

The question for investors is whether the gain is mostly hype or is now the time to buy Navitas? The stock's rise is mostly ...

Day trippers and tourists might be returning, but merchants in China’s northeastern Suifenhe town tell CNA the long-awaited ...

Discover six reasons EPD could surge in 2026—organic growth, ethane export upside, and market shifts—plus key risks. Click ...